Date clarification: July 21, 2026 is today, not tomorrow. Marsh (NYSE: MRSH) is scheduled to report 2Q26 results and host its earnings call this morning.
The key issue for Marsh heading into 2Q26 is not whether it can produce earnings growth—it likely can—but whether organic growth remains resilient as commercial P&C insurance pricing moderates. The Street’s setup is neutral-to-cautious: expectations call for roughly 3.6% consolidated underlying revenue growth, 3.1% in Risk & Insurance Services, a 29.3% operating margin, and $2.90 of EPS.
That is a notably more modest organic-growth hurdle than the company’s long-run profile and its 1Q26 performance. Consequently, the stock reaction will likely depend more on the quality and trajectory of growth—particularly at Marsh Risk—than on a modest EPS beat.
| Metric | 2Q26 expectation / focus |
|---|---|
| Consolidated underlying revenue growth | ~3.6% |
| Risk & Insurance underlying growth | ~3.1% |
| Operating margin | ~29.3% |
| EPS | ~$2.90 |
| Primary debate | Can Marsh sustain mid-single-digit organic growth despite easing insurance rates? |
Marsh Risk is the company’s largest earnings driver. In 1Q26, it delivered 4% underlying revenue growth, with 3% in U.S./Canada and 5% internationally. International growth was led by EMEA at 6% and Asia Pacific at 5%.
For 2Q, investors will want to see whether Marsh Risk can hold near that 3%–4% underlying-growth range. A result materially below the Street’s ~3.1% expectation would reinforce the concern that lower premium-rate increases are beginning to weigh more heavily on brokerage revenue growth. Conversely, a 4%-plus print—especially if U.S./Canada remains steady—would support the view that client retention, exposure growth, new business, specialty products, and international execution can offset pricing normalization.
What matters inside the number: - U.S./Canada organic growth versus the 3% delivered in 1Q. - International growth, especially EMEA and Asia Pacific. - Commentary on insurance-rate trends by major line, carrier behavior, and client demand. - New-business activity and retention, even if management provides only qualitative color.
Consulting was the upside contributor in 1Q26, with 5% underlying growth. Mercer grew 5%, supported by Wealth (+5%) and Health (+6%), while Career declined 2%. Marsh Management Consulting grew 6% organically.
That mix is important. If Risk & Insurance growth moderates, investors need Consulting—particularly Mercer Health, Mercer Wealth, and Marsh Management Consulting—to remain a reliable mid-single-digit grower.
A constructive report would show: - Continued mid-single-digit growth at Mercer Wealth and Health; - Stabilization or improvement in Mercer Career; - Sustained demand for management-consulting work despite macro and trade-policy uncertainty.
Marsh ended 2025 with its 18th consecutive year of reported margin expansion, and management has positioned the three-year Thrive program around operating-model optimization, automation, efficiency, and client-value initiatives.
In 1Q26, adjusted operating income grew 8% and adjusted margin held at 31.8%, despite only 4% underlying revenue growth. That demonstrates good cost discipline, but 2Q will be a more meaningful test of whether operating leverage can persist as top-line growth decelerates.
Watch for: - Consolidated adjusted operating margin relative to the roughly 29.3% consensus expectation; - Segment-margin performance in Risk & Insurance versus Consulting; - Compensation-cost growth, a key variable for a talent-intensive professional-services company; - Restructuring and implementation costs from Thrive, and any quantified savings outlook.
1Q26 GAAP results were distorted by a $425 million Greensill litigation charge, recorded in Risk & Insurance Services. As a result, reported operating income fell 12% year over year, even as adjusted operating income rose 8% and adjusted EPS increased 8% to $3.29.
For 2Q, investors should separate the operating result from legal-accounting noise:
Marsh repurchased approximately $750 million of stock in 1Q26, or about 4.2 million shares, following $2.0 billion of repurchases in 2025. The company also continues to pay a meaningful dividend.
The balance sheet carries approximately $20.6 billion of debt as of March 31, 2026, against $1.6 billion of corporate cash; fiduciary cash should not be viewed as freely available corporate liquidity. The company issued and repaid $600 million of senior notes during 1Q, suggesting ordinary refinancing activity rather than a major shift in capital structure.
The call should clarify whether Marsh intends to maintain its current repurchase cadence while funding: - Thrive investment and restructuring; - Smaller bolt-on acquisitions; - Litigation-related cash needs, if any; - Deleveraging priorities following the McGriff acquisition.
MRSH closed at $182.13 on July 20. The stock is up about 6% since April 1 and roughly 14% from its late-May low, but it has largely recovered rather than decisively rerated. That suggests investors are not pricing in an especially aggressive organic-growth reacceleration.
The first-quarter earnings release produced an initial favorable reaction—shares rose about 4.4% on April 16—but the move faded quickly. This time, an EPS beat without a convincing growth narrative may not be enough. The market is likely looking for evidence that Marsh can defend its premium valuation through a softer insurance-pricing environment.
MRSH enters 2Q26 with a relatively manageable earnings bar but a more consequential organic-growth and outlook bar. A clean result requires Risk & Insurance growth at or above expectations, continued Consulting resilience, and margin discipline that proves Thrive can offset a less favorable insurance-pricing backdrop. The largest downside risk is not a small EPS miss; it is evidence that organic growth is slipping below the low-single-digit range while legal uncertainty and restructuring costs remain elevated.
Research basis: Marsh’s 1Q26 earnings release; Marsh’s 4Q/full-year 2025 earnings release; Marsh’s July 17, 2026 market preview digest; and MRSH closing-price data through July 20, 2026.